additional experiments are needed to interpret these results. In future work we will compare IgG with known affinity to subclasses of CCP antigens to verify that our technique distinguishes these more subtle differences in epitope specificity. In addition, it will be investigated whether fine specificity may affect the progression to arthritis in ACPA+ arthralgia patients.

**REGULATION OF EXPRESSION AND FUNCTION OF NEGATIVE IMMUNOMODULATORY RECEPTORS IN B-CELLS: IMPLICATIONS FOR THE PATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS**

doi:10.1136/annrheumdis-2013-203219.26

1Amalia Zampoylaki, 1Christianna Choulaki, 1Irini Gergianaki, 1Garyfalia Papadaki, 1Antonis Fanoukis, 1Podromos Sidirooulos, 1Dimitrios T Boumpas, 2George Bertsias, 2Laboratory of Autoimmunity and Inflammation, Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Medical School, Heraklion, Greece; 1Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, 71300 Heraklion, Greece

**Background and Objectives** Fine tuning of B-cell activation and differentiation depends on convergent signals from the B-cell receptor (BCR), costimulatory/co-inhibitory membrane receptors, and Toll-like receptors. We sought to examine the expression and function of the coinhibitory receptors programmed death-1 (PD-1), PD-1 ligand-1 (PD-L1), and T lymphocyte attenuator (BTLA) in B-cells from healthy donors, and from patients with systemic lupus erythematosus (SLE), the prototype of systemic autoimmune disease characterised by activated B-cells and production of high-titer autoantibodies by long-lived plasma cells.

**Materials and Methods** Peripheral blood CD19+ B cells were purified from healthy donors (n = 11) and active SLE patients (n = 15; SLE disease activity index 8.3 ± 2.7 [mean ± SEM]). PD-1, PD-L1, and BTLA were examined by flow cytometry in naïve (CD19+CD27+), memory/transitional (CD19+CD27-), and plasma B-cells (CD19+CD27+) at baseline and following stimulation. Activation, differentiation, and proliferation (CFSE dilution) of B-cells were examined in the presence or absence of the BTLA ligand, HVEM. Western blot was used to assess the phosphorylation of intracellular kinases.

**Results** In healthy donors, the coinhibitory receptors PD-1 and PD-L1 were significantly upregulated on circulating plasma cells compared to transitional/memory and naïve B-cells (PD-1: 36 ± 7%, 14 ± 3%, 2.0 ± 0.5%; PD-L1: 94 ± 2%, 83 ± 5%, 62 ± 8%, respectively, p < 0.001). BTLA was expressed by 93–100% of B-cells, and mean fluorescence intensity was significantly higher in plasma-cells (334 ± 146 versus 127 ± 12 in naïve B-cells, p = 0.048). BCR activation enhanced the expression all three receptors in normal B-cells; addition of Cpg-ODN (TLR-9 ligand) further induced PD-1 and PD-L1 but not BTLA-expression, whereas addition of the cytokines IL-4, IL-10, or IL-21 reduced PD-1 and BTLA levels. In vitro crosslinking of BTLA resulted in reduction of BCR-induced phosphorylation of ERK, CD80/CD86 and BAFF-receptor expression, as well as in inhibition of cell proliferation (divided cells: 5.3 ± 0.4% versus 17.7 ± 0.1% in anti-IgM-stimulated cells). In comparative analysis, SLE patients exhibited significantly higher PD-1 expression on plasma-cells compared to healthy donors (65 ± 5% versus 36 ± 7%, p = 0.002), whereas there was no difference in PD-L1 or BTLA. Preliminary studies suggest distinct roles for PD-1 and BTLA in regulation of activation and maturation of B-cells in healthy controls and in the context of lupus.

**Conclusions** The coinhibitory receptors PD-1, PD-L1 and BTLA demonstrate differential expression among B-cell subsets and they are induced upon stimulation with important implications for the regulation of B-cell activation, proliferation and differentiation. Abrerrancies in the expression and function of coinhibitory receptors in SLE plasma B-cells could contribute to enhanced autoantibody-forming capacity and disease pathogenesis.

**SEMAPHORIN3A IS A POTENT B CELL REGULATORY MOLECULE IN SLE**

doi:10.1136/annrheumdis-2013-203219.28

Zahava Vadaas, Elias Toubi. Bnai-Zion Medical Center, Faculty of Medicine, Technion-Haifa, Israel

**Background/Purpose** Semaphorin3A (sem3A) is an important regulatory molecule, previously reported to play a role in the pathogenesis of rheumatoid arthritis and later by us in lupus glomerulonephritis. In addition, sema3A was shown to be a marker of T regulatory cells. A subpopulation of B cells, namely B regulatory cells (Bregs), was recently identified by us as CD19+CD27+IL-10+TGF-β++, and demonstrated to be of high sema3A expression.

We therefore asked whether serum levels of sema3A is altered in SLE patients, whether sema3A expression on B regs of these patients is different, and finally, whether the addition of soluble sema3A to